Antares Pharma, Inc. Partner, TEVA Pharmaceuticals USA, Introduces New Resources to Support Use of ANTARES' Patient-Friendly Injector for Growth Hormone Deficiency in Children
Published: Feb 02, 2010
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex: AIS) a leader in self injection drug delivery technology today announced that Teva USA has introduced new patient support resources for the Tjet® device and TEV-TROPIN® [somatropin (rDNA origin) for injection]. Antares licensed its novel delivery device to Teva, branded as Tjet® for delivering TEV-TROPIN® brand human growth hormone (hGH) to children who have growth failure due to inadequate secretion of normal endogenous growth hormone.